TEAM & PROJECTS

Xanthippi Koutsoumpou

FDA approved NP cellular hitchhicking system for targeted combination therapy and diagnosis

Glioblastoma (GBM) remains an incurable tumor with the Blood-Brain Barrier (BBB) to constitute a significant impediment for the delivery of therapeutics to the brain. Moreover, the complex intratumoral heterogeneity and dose-limiting toxicity remain serious problems in chemotherapeutic drugs’ efficacy.

In this project, we propose a new theranostic approach of GBM treatment that is based on a novel NP cellular hitchhiking system (NPCHS). The suggested NPCHS is thought to be able to cross the BBB upon intravenous administration, be directed toward the GBM by natural chemotaxis, contain multiple different therapeutic modalities for targeted combined therapy and non-invasive monitoring of therapeutic efficacy.

Promotor: Prof. Dr. Steven de Vleeschouwer

Co-promotor: Dr. Bella Manshian

List of Publications

Lenders V, Koutsoumpou X, Sargsian A, Manshian BB, Biomedical nanomaterials for immunological applications: ongoing research and clinical trials (2020), Nanoscale Advances